Weight Loss Improves Predicted 10-Year MACE and Type 2 Diabetes Risk, but Benefits Partially Rebound at 1 Year.

Obesity (Silver Spring)Aug 23, 2026 (epub)
Clinical ResearchCardiologyEndocrinology

Abdelrahman M Elshakankiry, Gary R Hunter, Cátia Martins et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of weight loss on predicted 10-year risks for major adverse cardiovascular events (MACE) and type 2 diabetes (T2D) in sedentary women with overweight. Among 221 participants, MACE risk decreased significantly from baseline to post-weight loss but rebounded at 1 year. Notably, the Diet-only group showed a greater reduction in MACE compared to Diet+Resistance.

Key findings

  • Mean BMI decreased from 28.3 to 23.9 kg m -2, then rebounded to 25.8 at 1 year.
  • MACE risk decreased significantly from baseline to post-weight loss (all p < 0.001).
  • T2D risk decreased in all groups but rebounded in Diet+Aerobic and Diet-only.
  • The Diet+Resistance group maintained a significant net reduction in T2D risk at 1 year (p = 0.003).

Why it matters

Understanding the impact of weight loss on cardiovascular and diabetes risks is crucial for developing effective interventions. This study highlights the importance of exercise modality in maintaining health benefits post-weight loss.

Source

PubMed · PMID 42634098

Published in Obesity (Silver Spring). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.